Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06012448 · ClinicalTrials.gov registry record · Phase 4
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
A Phase 4 study of Dermal Hypersensitivity Reaction, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06012448: Completed Phase 4 study of Dermal Hypersensitivity Reaction, sponsored by University of Michigan.
NCT06012448 is a Phase 4 study of Dermal Hypersensitivity Reaction that has completed, run by University of Michigan. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06012448, a Phase 4 study of Dermal Hypersensitivity Reaction, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction. This study will help better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might help treat this condition.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2025-03-25 |
| Phase | Phase 4 |
What the finished NCT06012448 record still lists
NCT06012448 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Dermal Hypersensitivity Reaction appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT06012448 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06012448 about?
NCT06012448 is a clinical study titled "The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction". This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction. This study will help better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might help treat this conditi...
What is the current status of trial NCT06012448?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2023-10-02. Estimated completion is 2025-03-25.
What conditions does trial NCT06012448 study?
This clinical trial studies the following conditions: Dermal Hypersensitivity Reaction.
What interventions are being tested in trial NCT06012448?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT06012448?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06012448 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06012448's enrollment target sits among peer trials
10 1941st of 2000 higher than 33 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI